This randomized clinical trial assessed the safety of ticagrelor compared to clopidogrel in patients with ST-elevation myocardial infarction (STEMI) treated with fibrinolytic therapy. The trial found that delayed administration of ticagrelor was noninferior to clopidogrel regarding major bleeding at 30 days, although minor bleeding rates were higher with ticagrelor. Overall, there was no significant efficacy benefit observed with ticagrelor after fibrinolysis in this patient population.
Related topics: